1. First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers. Issue 10 (23rd July 2022) Authors: Blank, Antje; Hohmann, Nicolas; Dettmer, Marlen; Manka‐Stuhlik, Anette; Mikus, Gerd; Stoll, Felicitas; Stützle‐Schnetz, Marlies; Thomas, Daniel; Exner, Evelyn; Schmitt‐Bormann, Beate; Schaller, Torsten; Laage, Rico; Schönborn‐Kellenberger, Oliver; Arndt, Michaela; Haefeli, Walter E.; Krauss, Jürgen Journal: Clinical and translational science Issue: Volume 15:Issue 10(2022) Page Start: 2366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗